We enable safe and efficient monitoring of tissues during cancer surgery without compromising workflows.
Rethinking surgery.
Marginum is developing groundbreaking tissue recognition technology, especially for oncological surgery.
Our technology assists in safe and efficient identification of cancerous tissue with minimal damage to healthy tissues.
Precise detection of tissue without additional invasive steps – based on internationally awarded research.
17.3.2025 | Marginum News
Oslo University Hospital has joined the HIVEN® multicenter trial investigating the clinical performance of the aspirate tissue monitoring method.
15.10.2024 | Marginum News
To date, this is the first patient in the world treated with fluorescence-guided aspirate tissue monitoring technology utilising the Marginum HIVEN® device.
28.6.2024 | Marginum News
The quality management system of Marginum has been assessed and certified as meeting the requirements of ISO 13485:2016 and EN ISO 13485:2016.
10.11.2023 | Marginum News
Almaral, Nostetta Ventures, and Redstone led the investment into Finnish medical technology company Marginum, coupled with Business Finland R&D loan.
22.3.2023 | Marginum News
Marginum Ltd has initiated its first-in-human clinical trials with the aspirate tissue monitor at the Kuopio University Hospital.
21.2.2023 | Tahko Ski Lift Pitch
Tahko Ski Lift Pitch winner Marginum is pioneering optic tissue monitoring with groundbreaking innovation borne from multidisciplinary UEF research.
Marginum is enabling better surgical performance and patient outcomes to answer the globally growing need for efficient oncological treatments.
Founded in 2020, Marginum is reforging the
technology of oncological surgery
With the developed tissue detection technology for surgery, Marginum aims to make a real impact by helping millions of patients and surgical professionals around the globe.
Location: Kuopio, Finland
Email: info@marginum.com